Reciprocal regulation of 17β-estradiol, interleukin-6 and interleukin-8 during growth and progression of epithelial ovarian cancer

Cytokine

Volumn 46, Issue 3, 2009, Pages 382-391

  Yang, Jie ^a,b,c   Wang, Yue ^a,d   Gao, Yan ^e   Shao, Jie ^a,b,c   Zhang, Xue Jun ^a,b,c   Yao, Zhi ^a,b,c  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Tianjin Key Laboratory of Cellular and Molecular Immunology   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^e TIANJIN THIRD CENTRAL HOSPITAL   (China)

Author keywords

17 Estradiol (E2); Interleukin 6 (IL 6); Interleukin 8 (IL 8); Ovarian cancer (OVCA)

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CYTOKINE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8; INTERLEUKIN 8 RECEPTOR; RECOMBINANT INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 8; RNA; TAMOXIFEN; WORTMANNIN; ESR1 PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; EPITHELIUM CELL; FEMALE; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; EPITHELIAL CELLS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; OVARIAN NEOPLASMS; RECEPTORS, INTERLEUKIN-6; RECEPTORS, INTERLEUKIN-8;

EID: 67349199124     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.03.013     Document Type: Article

References (49)

1. Risch H.A. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90 (1998) 1774-1786
2. Roa B.R., and Slotman B.J. Action and counter-action of hormones in human ovarian cancer. Anticancer Res 9 (1989) 1005-1007
3. Clinton G.M., and Hua W. Estrogen action in human ovarian cancer. Crit Rev Oncol Hematol 25 (1997) 1-9
4. Rodriguez C., Patel A.V., Calle E.E., Jacob E.J., and Thun M.J. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285 (2001) 1460-1465
5. Lacey Jr. J.V., Mink P.J., Lubin J.H., Sherman M.E., Troisi R., Hartge P., et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288 (2002) 334-341
6. Anderson G.L., Judd H.L., Kaunitz A.M., Barad D.H., Beresford S.A., Pettinger M., et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 290 (2003) 1739-1748
7. Folsom A.R., Anderson J.P., and Ross J.A. Estrogen replacement therapy and ovarian cancer. Epidemiology 15 (2004) 100-104
8. Mahlck C.G., Backstrom T., and Kjellgren O. Plasma level of estradiol in patients with ovarian malignant tumors. Gynecol Oncol 30 (1988) 313-320
9. Seiler P., Plenz G., and Deng M.C. The interleukin-6 cytokine system in embryonic development, embryo-maternal interactions and cardiogenesis. Eur Cytokine Netw 12 (2001) 15-21
10. Vanden B.W., Vermeulen L., De Wilde G., De Bosscher K., Boone E., and Haegeman G. Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. Biochem Pharmacol 60 (2000) 1185-1195
11. Horn F., Henze C., and Heidrich K. Interleukin-6 signal transduction and lymphocyte function. Immunobiology 202 (2000) 151-167
12. Miki S., Iwano M., Miki Y., Yamamoto M., Tang B., Yokokawa K., et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 250 (1989) 607-610
13. Nakajima K., Yamanaka Y., Nakae K., Kojima H., Ichiba M., Kiuchi N., et al. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J 15 (1996) 3651-3658
14. Okamoto M., Lee C., and Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 57 (1997) 141-146
15. Kurebayashi J. Regulation of interleukin-6 production from breast cancer cells and its clinical implications. Breast Cancer 7 (2000) 124-129
16. Barille S., Bataille R., and Amiot M. The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma. Eur Cytokine Netw 11 (2000) 546-551
17. Lou W., Ni Z., Dyer K., Tweardy D.J., and Gao A.C. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate 42 (2000) 239-242
18. Smith P.C., Hobisch A., Lin D.L., Culig Z., and Keller E.T. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 12 (2001) 33-40
19. Matsushima K., Baldwin E.T., and Mukaida N. Interleukin-8 and MCAF: novel leukocyte recruitment and activating cytokines. Chem Chem Immunol 51 (1992) 236-265
20. Onuffer J.J., and Horuk R. Chemokines, chemokine receptors and small-molecule antagonists: recent developments. Trends Pharmacol Sci 23 (2002) 459-467
21. Penson R.T., Kronish K., Duan Z., Feller A.J., Stark P., Cook S.E., et al. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 10 (2000) 33-41
22. Obata N.H., Tamakoshi K., Shibata K., Kikkawa F., and Tomoda Y. Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res 17 (1997) 337-342
23. Xu L., and Fidler I.J. Interleukin 8: an autocrine growth factor for human ovarian cancer. Oncol Res 12 (2000) 97-106
24. Abdollahi T., Robertson N.M., Abdollahi A., and Litwack G. Identification of interleukin 8 as an antagonist of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in the ovarian carcinoma cell line OVCAR3. Cancer Res 63 (2003) 4521-4526
25. Wang Y., Yang J., Gao Y., Du Y., Bao L., Niu W., et al. Regulatory effect of E2, IL-6 and IL-8 on the growth of epithelial ovarian cancer cells. Cell Mol Immunol 2 (2005) 365-372
26. Tempfer C., Zeisler H., Sliutz G., Haeusler G., Hanzal E., and Kainz C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol 66 (1997) 27-30
27. Radke J., Schmidt D., Bohme M., Scmidt U., Weise W., and Morenz J. Cytokine level in malignant ascites and peripheral blood of patients with advanced ovarian carcinoma. Geburtshilfe Frauenheilkunde 56 (1996) 83-87
28. Ivarsson K., Runesson E., Sundfeldt K., Haeger M., Hedin L., Janson P.O., et al. The chemotactic cytokine interleukin-8-a cyst fluid marker for malignant epithelial ovarian cancer?. Gynecol Oncol 71 (1998) 420-423
29. Toutirais O., Chartier P., Dubois D., Bouet F., Leveque J., Catros-Quemener V., et al. Constitutive expression of TGF-beta1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma. Eur Cytokine Netw 14 (2003) 246-255
30. Bengtsson A.K., Ryan E.J., Giordana D., Magaletti D.M., and Clark E.A. 17β-Estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells. Blood 104 5 (2004) 1404-1410
31. Brady H., Doubleday M., Gayo-Fung L.M., Hickman M., Khammungkhune S., Kois A., et al. Differential response of estrogen receptors α and β to SP500263, a novel potent selective estrogen receptor modulator. Mol Pharmacol 3 (2002) 562-568
32. Girasole G., Jilka R.L., Passeri G., Boswell S., Boder G., Williams W.C., et al. 17β-Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 89 (1992) 883-891
33. Rothwarf D.M., and Karin M. The NF-κB activation pathway; a paradigm in information transfer from membrane to nucleus. Sci STKE 5 (1999) 1-16
34. Pettersson K., Grandien K., Kuiper G.G.J.M., and Gustafsson J.A. Mouse estrogen receptor b forms estrogen response element-binding heterodimers with estrogen receptor a. Mol Endocrinol 11 (1997) 1486-1496
35. Crowley A.M., Hoare S., Mosselman S., and Parker M.G. Estrogen receptors a and b form heterodimers on DNA. J Biol Chem 272 (1997) 19858-19862
36. Brandenberger A.W., Tee M.K., and Jaffe R.B. Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. J Clin Endocrinol Metab 83 (1998) 1025-1028
37. Pujol P., Rey J.M., Nirde P., Roger P., Gastaldi M., Laffargue F., et al. Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 58 (1998) 5367-5373
38. Rutherford T., Brown W.D., Sapi E., Aschkenazi S., Munoz A., and Mor G. Absence of estrogen receptor-beta expression in metastatic ovarian cancer. Obstet Gynecol 96 (2000) 417-421
39. Bardin A., Hoffmann P., Boulle N., Katsaros D., Vignon F., Pujol P., et al. Involvement of estrogen receptor b in ovarian carcinogenesis. Cancer Res 64 (2004) 5861-5869
40. Satoh T., Nakafuku M., and Kaziro Y. Function of Ras as a molecular switch in signal transduction. J Biol Chem 267 (1992) 24149-24152
41. Qiu Y., Ravi L., and Kung H.J. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature 393 (1998) 83-85
42. Baggiolini M., Dewald B., and Moser B. Human chemokines: an update. Annu Rev Immunol 15 (1997) 675-705
43. Schumacher C., Clark-Lewis I., Baggiolini M., and Moser B. High- and low-affinity binding of GRO alpha and neutrophil-activating peptide 2 to interleukin 8 receptors on human neutrophils. Proc Natl Acad Sci USA 89 (1992) 10542-10546
44. Dumont R.A., Car B.D., Voitenok N.N., Junker U., Moser B., Zak O., et al. Systemic neutralization of interleukin-8 markedly reduces neutrophilic pleocytosis during experimental lipopolysaccharide-induced meningitis in rabbits. Infect Immun 68 (2000) 5756-5763
45. Barlic J., Andrews J.D., Kelvin A.A., Bosinger S.E., DeVries M.E., Xu L., et al. Regulation of tyrosine kinase activation and granule release through beta-arrestin by CXCRI. Nat Immunol 1 (2000) 227-233
46. Feniger-Barish R., Yron I., Meshel T., Matityahu E., and Ben-Baruch A. IL-8-induced migratory responses through CXCR1 and CXCR2: association with phosphorylation and cellular redistribution of focal adhesion kinase. Biochemistry 42 (2003) 2874-2886
47. Lee L.F., Louie M.C., Desai S.J., Yang J., Chen H.W., Evans C.P., et al. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene 23 (2004) 2197-2205
48. Belcher S.M., and Zsarnovszky A. Estrogenic actions in the brain: estrogen, phytoestrogens, and rapid intracellular signaling mechanisms. J Pharmacol Exp Ther 299 (2001) 408-414
49. Kelly M.J., and Wagner E.J. Estrogen modulation of G-protein-coupled receptors. Trends Endocrinol Metab 10 (1999) 369-374